Menomadin Foundation
VC Fund
Menomadin Foundation is a VC fund focused on Health Care and Medical Device. Menomadin Foundation
- Total investments:
- 7
- Last investment:
- Lead investor:
- 29%
Last updated:
For AI agents: llms.txt
Industries Menomadin Foundation invests in
Health CareMedical DeviceMachine LearningArtificial IntelligenceAgTech
Stages Menomadin Foundation invests in
Series ASeedFunding RoundVenture - Series Unknown
Countries Menomadin Foundation invests in
IsraelUnited States
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Investment Focus
Industry
- Health Care 2 (29%)
- Medical Device 2 (29%)
- Machine Learning 2 (29%)
- Artificial Intelligence 2 (29%)
- AgTech 1 (14%)
Stage
- Series A 3 (43%)
- Seed 1 (14%)
- Funding Round 1 (14%)
- Venture - Series Unknown 1 (14%)
Country
- Israel 3 (43%)
- United States 3 (43%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Eliran Keren
CEO impact investment and measurement
|
CEO impact investment and measurement | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Voltify
|
Voltify is a climate tech company that offers decarbonization solutions for the freight rail industry. | $30M / Seed / Mar 31, 2026 | |
Momentick
|
Momentick is making a net-zero future a reality. Our advanced algorithms unlock the power of satellite imagery to measure, monitor and reduce GHG emissions. We deliver the technology industries and regulatory bodies need to autonomously detect & monitor emissions on a global scale.--- Precise Emissions Data --- Advanced algorithms applied tosatellite imagery to deliver the precise data crucial for accurately detecting and monitoring emissions on and offshore on a global scale. --- Advanced Multi-satellite imagery --- Emissions intelligence autonomously derived from a wide range of satellite sources for precise detection, high-frequency monitoring and customized reporting. --- Compliance and Verification --- Emissions performance tracked over time to verify regulatory compliance, inform decision-making and drive green energy projects. | $5M / Jan 14, 2025 | |
enSights
|
enSights provides a centralized picture of the status and requirements of your renewable energy assets. Collect, store, and learn from your digital assets in a single, centralized location, leveraging the most advanced real-time monitoring and machine learning algorithms to optimize performance and minimize consumption at scale. | $10M / Series A / Dec 04, 2024 | |
SupPlant
|
SupPlant is a company in the field of “IOT” in agriculture. By changing the basic concept of irrigation methods, the SupPlant's unique technology can save water on global scales and improve productivity and yields. During the past 4 years, SupPlant developed a unique artificial intelligence system that is able to analyze data generated fromcrops through sensors and translate this data into irrigation commands. | $27M / Venture - Series Unknown / Mar 14, 2022 | |
|
SupPlant
|
SupPlant is a company in the field of “IOT” in agriculture. By changing the basic concept of irrigation methods, the SupPlant's unique technology can save water on global scales and improve productivity and yields. During the past 4 years, SupPlant developed a unique artificial intelligence system that is able to analyze data generated fromcrops through sensors and translate this data into irrigation commands. | $10M / Venture - Series Unknown / Jun 13, 2021 | |
EyeControl
|
EyeControl is a pioneer of medical technology, specializing in innovative communication solutions that address unmet healthcare needs. We implement disruptive AI-technologies that connect people and bridge information barriers, facilitating better medical care and decision-making. Our eye-tracking wearable and smart platforms empowercomprehensive, round-the-clock, bi-directional connectivity between patients with communication difficulties, their families, and medical teams. Using adaptive, ML-based pattern recognition, eye gestures are analyzed and converted to real-time communication and actionable clinical data for patients with various levels of cognition. Established in 2016 by individuals, who share unique personal connections to Locked-in patients, EyeControl is a privately held, rapidly growing startup. Recognized as spearheads of cutting-edge medical innovation, the company is supported by the European Innovation Council, Israel Innovation Authority, investors and advisors representing various sectors.The EyeControl device is FDA listed, CE marked, ISO certified, AMAR registered, and HIPAA compliant; it is federally reimbursed in Israel, the UK, and the US. Clinical trials validating its efficacy in detecting and mitigating Delirium are underway in Israel and the US. | Series A / Aug 12, 2020 | |
Biobeat
|
Biobeat develops a wearable device for continuous, noninvasive, accurate, medical-grade monitoring of vital signs that include blood pressure, oxygen saturation, respiratory rate, heart rate, consciousness, cardiac output, stroke volume, body temperature, steps, and sweat. Its wearable device automatically uploads the recorded data to asmartphone-based application and to the cloud, where the application can monitor it remotely. Caretakers can intervene if needed, and users can receive alerts directly from the app. This provides caretakers with an important tool to assist in disease management and optimize clinical outcomes. The Biobeat system also facilitates remote monitoring of patients with a variety of medical issues. Ultimately, this solution allows patients to be treated in their homes. It can monitor stationary patients as well as those who perform outdoor activities. In 2018, Biobeat received FDA 510K clearance (K181006) for its monitoring system and partnered with DRIVe, a division of the Biomedical Advanced Research and Development Authority, to develop a wearable monitoring device that diagnoses the flu and infections before any symptoms appear. In August 2019, Biobeat received 510K FDA clearance for its patch and watch. | $8M / Series A / Mar 01, 2020 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
SaaS Investors
99,274 investors
Health Care Investors
43,014 investors
Artificial intelligence Investors
40,702 investors
Machine Learning Investors
17,935 investors
Medical Device Investors
11,047 investors
Agriculture (agtech) Investors
10,346 investors
SaaS VC Funds
61,208 investors
Health Care VC Funds
32,370 investors
Artificial intelligence VC Funds
27,398 investors
FAQ
What does Menomadin Foundation invest in?
Menomadin Foundation invests primarily in Health Care, Medical Device and Machine Learning startups, most often at Series A and Seed stage. Most of the 7 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Menomadin Foundation?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Menomadin Foundation?
The team at Menomadin Foundation includes Eliran Keren (CEO impact investment and measurement). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
